港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

泰德医药

30.600

0.000

成交量：- -

成交额：- -

市值：43.45亿

市盈率：- -

高：30.600

开：30.600

低：30.600

收：30.600

数据加载中...

总览公司新闻公告

公司资料

公司名字：

泰德医药

交易所：

SEHK

成立时间：

2020

员工人数：

- -

公司地址：

Shaoxing,Zhejiang Province,China

官网：

http://www.medtideinc.com

邮编：

- -

电话：

- -

传真：

- -

简介：

根据弗若斯特沙利文的资料,就2023年销售收入而言,我们是全球第三大专注于多肽的合约研究、开发及生产机构(「CRDMO」)。根据弗若斯特沙利文的资料,我们亦是全球专注于多肽的最全面的CRDMO之一,提供从早期发现、临床前研究及临床开发以至商业化生产的全周期服务。

董事

名称

职位

徐琪

董事长，执行董事，薪酬委员会委员，提名委员会主席

李湘

执行董事

李湘莉

执行董事

Cheng Tao

执行董事

李玲梅

执行董事

朱迅

独立非执行董事，薪酬委员会主席，审核委员会委员

于常海

独立非执行董事，提名委员会委员，审核委员会委员

夏心晟

独立非执行董事，薪酬委员会委员，提名委员会委员，审核委员会主席

吴一晖

非执行董事

颜喜亚

监事会主席，股东代表监事

吴海刚

股东代表监事

傅红英

职工代表监事

股东

名称

职位

徐琪

首席执行官

徐伟群

财务总监

李玲梅

董事会秘书，联席公司秘书

李忠成

联席公司秘书

Cheng Tao

首席商务官

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/03880/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"03880","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03880\",,,,,undefined,":{"symbol":"03880","market":"HK","secType":"STK","nameCN":"泰德医药","latestPrice":30.6,"timestamp":1751007996193,"preClose":30.6,"halted":9,"volume":0,"greyMarket":{"tag":"暗盘","latestPrice":30.6,"preClose":30.6,"latestTime":"06-27 15:06:36","volume":0,"timestamp":1751007996193},"delay":0,"floatShares":142000000,"shares":142000000,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"06-27 15:06:36","open":30.6,"high":30.6,"low":30.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1751247000000},"marketStatusCode":8,"adr":0,"listingDate":1751212800000,"exchange":"SEHK","adjPreClose":30.6,"openAndCloseTimeList":[[1750987800000,1750996800000],[1751000400000,1751011200000]],"volumeRatio":0,"ipoDetail":{"name":"泰德医药","exchange":"SEHK","listingDate":"2025-06-30","sharesOutstanding":142000000,"sharesFloat":142000000,"offerAmount":16800000,"priceRange":"28.400 - 30.600","market":"HK","openProspectusDate":"2025-06-20","openProspectusUrl":"https://staticpdf.iqdii.com/stockdata/notice/03880/2025/2025062000022_c.pdf","purchaseBeginDate":"2025-06-20","purchaseEndDate":"2025-06-25","winningDate":"2025-06-27","currency":"HKD","minPurchaseQuantity":100,"peRate":68.75,"use":"1、约76.4%（或314.0百万港元）将用于在美国及中国建设设施以进一步扩大公司服务能力及产能；\n2、约4.1%（或16.9百万港元）将用于扩张中国的产能；\n3、约9.5%（或39.2百万港元）将用于在更多地区建立销售及售后服务网点，以丰富公司全球业务及扩大公司客户群；\n4、约10.0%（或41.1百万港元）将用于公司营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司主要提供(i)CRO服务，即多肽NCE发现合成；及(ii)CDMO服务，即多肽CMC开发以及商业化生产。","subscribed":0,"marketCap":4339000000,"minimumCapital":3090.85,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,150000,200000,250000,300000,350000,400000,450000,500000,600000,700000,840000"},"greyMarketDetail":{"greyDate":"2025-06-27","greyDateTimestamp":1750953600000,"greyOpeningTime":1751012100000,"greyClosingTime":1751020200000,"showGreyQuote":true,"openProspectusDate":"2025-06-20","listingDate":"2025-06-30"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03880\",,,,,undefined,":{"symbol":"03880","floatShares":142000000,"roa":"--","roe":"--","lyrEps":0,"shares":142000000,"dividePrice":0,"high":30.6,"amplitude":0,"preClose":30.6,"low":30.6,"week52Low":30.6,"pbRate":"--","week52High":30.6,"institutionHeld":0,"latestPrice":30.6,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":30.6},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":672607238,"yearFounded":2020,"address":"Shaoxing,Zhejiang Province,China"},"stockCompanyDetail":{"websiteUrl":"http://www.medtideinc.com","compareEarnings":[{"period":"1week","weight":0.0468},{"period":"1month","weight":0.0403},{"period":"3month","weight":0.0384},{"period":"6month","weight":0.2108},{"period":"1year","weight":0.3447},{"period":"ytd","weight":0.2126}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"根据弗若斯特沙利文的资料,就2023年销售收入而言,我们是全球第三大专注于多肽的合约研究、开发及生产机构(「CRDMO」)。根据弗若斯特沙利文的资料,我们亦是全球专注于多肽的最全面的CRDMO之一,提供从早期发现、临床前研究及临床开发以至商业化生产的全周期服务。","exchange":"SEHK","name":"泰德医药","nameEN":"MEDTIDE"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"03880\",market:\"HK\",,,undefined,":{"directors":[{"name":"徐琪","position":"董事长，执行董事，薪酬委员会委员，提名委员会主席"},{"name":"李湘","position":"执行董事"},{"name":"李湘莉","position":"执行董事"},{"name":"Cheng Tao","position":"执行董事"},{"name":"李玲梅","position":"执行董事"},{"name":"朱迅","position":"独立非执行董事，薪酬委员会主席，审核委员会委员"},{"name":"于常海","position":"独立非执行董事，提名委员会委员，审核委员会委员"},{"name":"夏心晟","position":"独立非执行董事，薪酬委员会委员，提名委员会委员，审核委员会主席"},{"name":"吴一晖","position":"非执行董事"},{"name":"颜喜亚","position":"监事会主席，股东代表监事"},{"name":"吴海刚","position":"股东代表监事"},{"name":"傅红英","position":"职工代表监事"}],"executives":[{"name":"徐琪","position":"首席执行官"},{"name":"徐伟群","position":"财务总监"},{"name":"李玲梅","position":"董事会秘书，联席公司秘书"},{"name":"李忠成","position":"联席公司秘书"},{"name":"Cheng Tao","position":"首席商务官"}]},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/03880\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"03880\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"03880\",market:\"HK\",delay:false,,,undefined,":{}}}